PPADS tetrasodium

Cat. No.: HY-101044 Purity: ≥95.0%: FAQs
Data Sheet SDS COA Handling Instructions

PPADS tetrasodiuma is a non-selective P2X receptor antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC₅₀s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC₅₀~0.9 mM) and recombinant P2Y4 (IC₅₀~15 mM) receptors. PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca²⁺ exchanger in guinea pig airway smooth muscle.

For research use only. We do not sell to patients.

PPADS tetrasodium Chemical Structure

CAS No. : 192575-19-2

Size	Price	Stock	Quantity
Solution
10 mM * 1 mL in Water	USD 198	In-stock	Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL ready for reconstitution	USD 198	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	USD 60	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 150	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 230	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE PPADS tetrasodium

•J Biol Chem. 2021 Sep 3;101166. [Abstract]

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

PPADS tetrasodiuma (1-30 μM; 10-50 minutes) inhibits Na+/Ca2+ exchanger reverse mode (NCXREV) in a time- and concentration dependent manner^[2].
PPADS tetrasodiuma is effective at other native and recombinant P2XRs. At human P2XRs sensitivity to PPADS tetrasodiuma depended on the subtype and is highest at the hP2X1, -2, -3, -5, and -7Rs with an IC₅₀ of ~1-3 and ~30 μM for the hP2X4R^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PPADS tetrasodiuma (15-60 mg/100g body weight (BW); i.p.; every 12 hours for 8 days) inhibits glomerular mesangial cells (MC) proliferation without altering proliferation of non-MC in vivo in mesangial proliferative glomerulonephritis^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley ratsweighing 160 to 200 g (anti-Thy1 disease mode)^[4]
Dosage:	15 mg/100g BW, 30 mg/100g BW, 60 mg/100g BW
Administration:	i.p.; every 12 hours for 8 days (the first PPADS injection was administered 60 minutes after disease induction, and the loading dose always contained double the amount of PPADS compared to the following injections.)
Result:	Specifically and dose-dependently reduced early (day 3) glomerular mesangial cell proliferation without altering proliferation of non-MC.

Molecular Weight

599.30

Appearance

Solid

Formula

C₁₄H₁₀N₃Na₄O₁₂PS₂

CAS No.

192575-19-2

SMILES

O=S(C1=CC=C(/N=N/C2=NC(C)=C(O)C(C=O)=C2COP(O[Na])(O[Na])=O)C(S(=O)(O[Na])=O)=C1)(O[Na])=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 50 mg/mL (83.43 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6686 mL	8.3431 mL	16.6861 mL
5 mM	0.3337 mL	1.6686 mL	3.3372 mL
10 mM	0.1669 mL	0.8343 mL	1.6686 mL

*Please refer to the solubility information to select the appropriate solvent.

Purity & Documentation

Purity: ≥95.0%

Select Batch:

Data Sheet (282 KB) SDS (252 KB)

COA (257 KB)

Handling Instructions (2659 KB)

References

[1]. Flores-Soto E, et al. PPADS, a P2X receptor antagonist, as a novel inhibitor of the reverse mode of the Na⁺/Ca²⁺ exchanger in guinea pig airway smooth muscle. Eur J Pharmacol. 2012 Jan 15;674(2-3):439-44. [Content Brief]

[2]. Huo H, et al. Mapping the binding site of the P2X receptor antagonist PPADS reveals the importance of orthosteric site charge and the cysteine-rich head region. J Biol Chem. 2018 Aug 17;293(33):12820-12831. [Content Brief]

[3]. Einfluss von ATP und seinen Derivaten auf die Aktivierung von Monozyten.

[4]. Rost S, et al. P2 receptor antagonist PPADS inhibits mesangial cell proliferation in experimental mesangialproliferative glomerulonephritis. Kidney Int. 2002 Nov;62(5):1659-71. [Content Brief]